Some families first learn about advanced gastric cancer after weeks of food coming back up. An endoscopy shows a tumor where the esophagus meets the stomach, and the initial conversation may involve total gastrectomy. After further imaging, the message can change: surgery is not technically impossible, but this center cannot do it, and metastasis is suspected. To relatives, that sounds like surgery has been abandoned. In practice, that single sentence usually reflects three separate questions being weighed at once.
The first is resectability — can the tumor be removed? Cancers at the gastroesophageal junction can extend upward into the esophagus and sideways toward the pancreas or spleen. Removing them may require partial resection of neighboring organs and a chest approach (thoracotomy), which is a different operation in difficulty and recovery from a standard gastrectomy. The second is operability — can this particular body tolerate that operation? Heart and lung function, kidney function, nutritional status, recent weight loss, and everyday activity level all belong here. The third is whether removal would actually help. If disease has already spread to distant sites or the peritoneum, taking out the primary tumor does not remove what remains throughout the body, which is why systemic treatment usually comes first. "Can it be done" and "would it help" are separate axes.
"Suspected metastasis" is also not the same as confirmed metastasis. When CT shows an ambiguous nodule or lymph node, PET-CT adds metabolic information, and a biopsy or direct inspection of the abdominal cavity may be needed. Each test answers a different question, so clinicians stop at "suspected" until the results line up. While waiting, the most useful thing a family can do is ask which findings would change the plan, and write the answers down.
It also helps to clarify what chemotherapy is aiming for. Sometimes the goal is to lower recurrence risk around surgery. When resection is not appropriate, the goal shifts toward slowing progression, easing symptoms, and preserving daily function. In that setting, success is often measured as shrinkage or stability maintained over time rather than disappearance of the tumor. How much response occurs, and for how long, varies widely between individuals and cannot be promised in advance. Occasionally, a strong response reopens the surgical discussion, so "no surgery now" is not always "no surgery ever."
In gastric cancer, tissue results determine which drugs are available. Markers such as HER2 and PD-L1 decide whether targeted therapy or immunotherapy can be added, so the first infusion date sometimes waits a few days on pathology. That wait is part of choosing the combination, not a delay in care.
Age alone does not set treatment intensity. Many teams use a comprehensive geriatric assessment — comorbidities, current medications, mobility and daily function, cognition, nutrition, and caregiving support — rather than the number of years. Someone with preserved reserve may start near standard doses; when reserve is limited, treatment may begin with fewer agents or reduced doses and be adjusted according to response and side effects. Starting low is a legitimate plan, not a lesser one.
Restoring the ability to eat is foundational rather than peripheral. A stent placed across the esophagogastric narrowing is intended to reopen a passage for food and fluids, slowing further weight and muscle loss and building enough reserve to tolerate treatment. After placement, small frequent meals eaten slowly while sitting upright, with sips of liquid alongside, are generally safer than large ones. Tough, fibrous, or large pieces of food can obstruct the stent, so finer preparation helps. If swallowing remains inadequate, a feeding tube through the nose or a gastrostomy/jejunostomy are other options.
If care is transferred to another hospital, move the records with the patient: imaging discs (endoscopy, CT, PET-CT), radiology reports, pathology reports with borrowed blocks or slides, a referral letter, and a current medication list. Asking a few questions at the new clinic — is the goal cure or control, what changes if metastasis is confirmed, under what conditions surgery could be reconsidered, and what level of side effects would prompt a pause or a change — makes later decisions considerably easier.
Seek urgent care rather than waiting for the next appointment if any of the following appear: inability to keep down even water, fever of 38°C or higher with chills, black or bloody vomit or black stools, sudden severe chest or back pain, or reduced urine output with dizziness on standing.
Families often get stuck asking which choice is "right." In practice, options narrow as results arrive, and the family's task is to put their goals into words the medical team can work with. Saying that time spent eating and walking matters, not only length of survival, is information that genuinely shapes the plan.
This article is general information and does not replace individual diagnosis or medical care. Please discuss any decisions about treatment, testing, or medication with your own medical team.